Results 151 to 160 of about 101,340 (329)
Ropinirole: A dopamine agonist for the treatment of Parkinson’s disease [PDF]
Mary D. Kuzel
openalex +1 more source
Abstract Background Evidence suggests that female gender represents a risk factor for the development of motor/nonmotor fluctuations and dyskinesia in Parkinson's disease (PD). So far, no prospective study has analyzed this aspect in relation to the introduction of levodopa treatment.
Maria Teresa Pellecchia+41 more
wiley +1 more source
Biotransformation of
Sophie Sarre+3 more
openalex +1 more source
Levodopa‐Carbidopa Intestinal Gel in an Outpatient Setting: A 10‐Year Experience
Movement Disorders Clinical Practice, EarlyView.
Alessandro Magliozzi+7 more
wiley +1 more source
Management of Anxiety in Parkinson's Disease
ABSTRACT Background Anxiety is a common, distressing, hard‐to‐diagnose and hard‐to‐treat symptom in Parkinson's disease. No formal guidelines exist to assist management. Objective We provide a pragmatic guide to detecting and managing anxiety in Parkinson's disease.
Alex J. Berry+4 more
wiley +1 more source
Several reports have shown that some dopamine receptor ligands modulate the ischemia–reperfusion injury in animal models; however, its underling mechanisms are still unclear. In this study, we sought to establish an in vitro experimental model of hypoxia/
Saori Shimada+5 more
doaj
Dopamine agonists both stimulate and inhibit prolactin release in GH4ZR7 cells [PDF]
Annisa Chang, Shin Sh
openalex +1 more source
Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a well‐established therapy in advanced Parkinson's disease (PD) improving motor and non‐motor signs including sleep. The mechanisms of sleep improvement are insufficiently understood.
Julia Steinhardt+6 more
wiley +1 more source